Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 34-38

  Priyadarshini, ^a   Singh, Shrawan Kumar ^b   Tandon, Chanderdeep ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antilithiatic; Calcium oxalate; Human phosphate cytidylyltransferase 1; Matrix protein; Matrix assisted laser desorption ionization time of flight (MALDI TOF MS)

Indexed keywords

CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE;

ADULT; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CALCIUM OXALATE STONE; CONTROLLED STUDY; CRYSTALLIZATION; DATA BASE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NEPHROLITHIASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEIN PURIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STONE FORMATION;

CALCIUM OXALATE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; CRYSTALLIZATION; HUMANS; KIDNEY CALCULI; MASS SPECTROMETRY;

EID: 69849095121     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.06.041     Document Type: Article

References (26)

1. Ryall R.L., Chauvet M.C., and Grover P.K. Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals. BJU Int 96 (2005) 654-663
2. Fleisch H. Inhibitors and promoters of stone formation. Kidney Int 13 (1978) 361-371
3. Dussol B., and Berland Y. Urinary kidney stone inhibitors: what is the news?. Urol Int 60 (1998) 69-73
4. Coe F.L., and Parks J.H. New insights into the pathophysiology and treatment of nephrolithiasis: New research venues. J Bone Miner Res 12 (1997) 522-533
5. Hess B., Nakagawa Y., Parks J.H., and Coe F.L. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260 (1991) F569-F578
6. Asplin J.R., Arsenault D., Parks J.H., Coe F.L., and Hoyer J.R. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 53 (1998) 194-199
7. Hoyer J.R., Otvos Jr. L., and Urge L. Osteopontin in urinary stone formation. Ann NY Acad Sci 760 (1995) 257-265
8. Pillay S., Asplin J.R., and Coe F.L. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol 275 (1998) F255-FF61
9. Atmani F., and Khan S.R. Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res 23 (1995) 95-101
10. Stapleton A.M.F., and Ryall R.L. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol 75 (1995) 712-719
11. Coe F.L., Nakagawa Y., Asplin J., and Parks J.H. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab 20 (1994) 378-384
12. Wesson J.A., et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14 (2003) 139-147
13. Hess B. Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20 (1994) 393-398
14. Lieske J.C., and Deganello S. Nucleation, adhesion and internalization of calcium containing urinary crystals by renal cells. J Am Soc Nephrol 10 suppl (1999) S422-S429
15. Randall A. The origin and growth of renal calculi. Ann Surg 105 (1937) 1009-1017
16. Aggarwal S., Tandon C., Forouzandeh M., Singla S.K., Kiran R., and Jethi R.K. Role of biomolecules from human renal stone matrix on COM crystal growth. Mol Cell Biochem 210 (2000) 109-119
17. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
18. Chutipogtanate S., Nakagawa Y., Sritippayawan S., et al. Identification of human urinary trefoil factor1 as a novel calcium oxalate crystal growth inhibitor. J Clin Invest 115 (2005) 3613-3622
19. Aggarwal S., Tandon C., Forouzandeh M., Singla S.K., Kiran R., and Jethi. Role of protein inhibitor isolated from human renal stone matrix in urolithiasis. Indian J Biochem Biophy 42 (2005) 113-117
20. Kaur T., Bijarnia R.K., Singla S.K., and Tandon C. Purification and characterization of an anticalcifying protein from the seeds of Trachyspermum ammi(L.). Protein Pept Let 16 (2009) 173-181
21. Bijarnia RK, Kaur T, Singla SK, Tandon C. A novel calcium oxalate crystal growth inhibitory protein from the seeds of Dolichos biflorus (L.). Protein J 2009;28:161-168.
22. Leah J.H., and Toback F.G. Amino acid modulation of renal phosphatidylcholine biosynthesis in the rat. J Clin Invest 65 (1980) 741-745
23. Khan S.R., Shevock P.N., and Hackett R.L. Presence of lipids in urinary stones: results of preliminary studies. Calcif Tissue Int 42 2 (1988) 91-96
24. Priyadarshini, Bijarnia R.K., Kaur T., Singh S.K., and Tandon C. Comparison of the inhibitory activity of isolated lipids and proteins from calcium oxalate stones. Ind J Urol 24 2 (2008) S111
25. Zeisel S.H., and Blusztajn J.K. Choline and human nutrition. Annu Rev Nutr 14 (1994) 269-296
26. Neǐmark A.I., Zhukov V.N., and Fidirkin A.V. Use of isradipine and lipostabil for protection of the kidney during extracorporeal lithotripsy. Urol Nefrol (Mosk) 6 (1998) 19-21